SILVER SPRING
Tremfya label expanded for joint damage prevention
- Sponsor
- Johnson & Johnson $JNJ
- Drug
- Tremfya · guselkumab
- Indication
- joint damage prevention
FDA approved a supplemental BLA for Tremfya to include evidence supporting its efficacy in preventing further joint damage.
Read original at drugs.com ↗Drug Watch — recent news on Tremfya
- J&J, Reporting $25B In Q2 Sales, Launches Campaign For Psoriasis Pill 07/16/2026 - MediaPost
- Tremfya surges, Icotyde gains ground as J&J raises bar for 2026 - FirstWord PHARMA
- J&J Raises 2026 Outlook as Tremfya, Darzalex Fuel Q2 Beat Despite Stelara, Abiomed Headwinds - finance.biggo.com
- J&J medtech miss overshadows earnings beat - Reuters
- No patent protection for Stelara? No problem for J&J as Tremfya fills the void - Fierce Pharma